الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 59 |  |  |
| | | from | 59 | | |
Abstract
Sometimes called degenerative joint disease or degenerative arthritis, osteoarthritis (OA) is the most common chronic condition of the joints. OA can affect any joint, but it occurs most often in knees, hips, lower back and neck.
Although OA occurs in people of all ages, osteoarthritis is most common in people older than 65. Common risk factors include increasing age, obesity, previous joint injury, overuse of the joint, weak thigh muscles and genes.
This disease requires the development of cartilage-sparing interventions that are noninvasive, safe, and cost-effective. Hence, Platelet-rich plasma was first evaluated in 1987.
Platelet-rich plasma is theorized to work via growth factors and anti-inflammatory cytokines that help inhibit destruction or perhaps even regenerate cartilage in OA.
The most important finding in this review was that PRP may improve short-term outcomes in knee OA.
Platelet-rich plasma appears to cause a statistically significant improvement in patient outcomes when compared with HA during the same time period.
Platelet-rich plasma appears to have the most benefit in younger patients with less advanced OA. But There is insufficient evidence to draw conclusions about PRP in joint OA at sites other than the knee.
Many of the studies reviewed discussed the modalities or preparation and platelet counts in the preparation given, but there is no evidence to support the use of one method over another.
A single- versus double-spinning approach to PRP has a statistically significant difference in adverse reactions favoring the single-spinning approach.
There are many limitations in this review but the largest one is that the majority of the evidence on this topic is from case series. Thus, no definitive recommendations about the use of PRP in OA can be made.